超越第三次EGFR-TKI获得阻力的战略:机遇和挑战
Xuexue Zhou1,2, Liang Zeng2, Zhe Huang2,3
1Medical College, Jishou University, Jishou, China.
Cancer medicine
|May 5, 2025
概括
第三代EGFR-TKI彻底改变了非小细胞肺癌的治疗方法,但耐药性很常见. 本综述探讨了抵抗机制和克服获得性抵抗的新疗法,重点关注中枢神经系统转移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体 (EGFR) 突变驱动非小细胞肺癌 (NSCLC).
- 第三代EGFR氨酸激酶抑制剂 (EGFR-TKI) 是先进的EGFR突变NSCLC的第一线治疗方法.
- 对EGFR-TKI获得的耐药性是一个重大的临床挑战.
研究的目的:
- 系统地审查NSCLC中对第三代EGFR-TKI获得性耐药性的分子机制.
- 专注于中枢神经系统 (CNS) 转移所带来的临床挑战.
- 评估诊断模式和新兴的治疗策略,以克服耐药性.
主要方法:
- 对临床前和临床研究的系统文献综述.
- 抵抗机制的分类为EGFR依赖的 (在目标上) 和EGFR独立的 (在目标之外) 途径.
- 对诊断工具和新型治疗方法的评估.
主要成果:
- 抵抗机制包括目标突变 (例如C797S) 和目标外途径 (例如MET放大,HER2激活).
- 中枢神经系统 (CNS) 转移带来了独特的临床挑战.
- 新兴策略包括第四代EGFR-TKI,组合疗法和抗体-药物联合体 (ADC).
结论:
- 了解耐药机制对于制定有效的治疗策略至关重要.
- 新的疗法和组合方法在克服获得的抗性方面表现有前途.
- 目前正在进行的临床试验对于推进EGFR突变NSCLC的治疗模式至关重要.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
